Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial Included are 1,096 transplants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results